Clinical Trial Update: Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression [Phase 3]

View source ↗

Summary

A Phase 3 efficacy study evaluating lisdexamfetamine for bipolar depression has been terminated; no efficacy results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression

Drugs mentioned

• Vyvanse (lisdexamfetamine dimesylate)

Snippet

Sponsor: Lindner Center of HOPE | Conditions: Bipolar Depression | Phase 3 | Status: TERMINATED